Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;25(12):e2013-e2016.
doi: 10.1002/ONCO.13516. Epub 2020 Oct 2.

A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors

Spyridon Gennatas #  1 , Florence Chamberlain #  1 , Alannah Smrke  1 , James Stewart  1   2 , Andrew Hayes  1   2 , Lorna Roden  1 , Christina Messiou  1   2 , Jie-Ying Kowa  1   3 , Anna Estival  4 , Dharmisha Chauhan  1 , Khin Thway  1   2 , Cyril Fisher  5 , Winette T A van der Graaf  1   2   6   7 , Robin L Jones  1   2 , Charlotte Benson  1
Affiliations

A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors

Spyridon Gennatas et al. Oncologist. 2020 Dec.

Abstract

Introduction: Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent oral vinorelbine.

Materials and methods: A retrospective review of patients treated with vinorelbine 90 mg orally on days 1, 8, and 15 of a 28-day cycle from January 2004 to July 2019 was performed. Response was assessed using RECIST version 1.1. Descriptive statistics were employed.

Results: A total of 29 patients were included. Response rate was 20.7% (6/29), and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%), and diarrhea (4/26, 13.8%).

Conclusion: Single-agent oral vinorelbine is an effective, safe, and well-tolerated treatment for DT. It represents a new oral alternative for management of DT.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1
Figure 1
Axial T2 weighted image (T2WI) magnetic resonance imaging (MRI) of the pelvis. MRI at baseline (A) and following 26 months of treatment (B) with vinorelbine. The large intermediate T2 signal tumor (arrow) arises from right obturator internus muscle, compressing and displacing the rectum and prostate. Following treatment (B), the tumor (arrow) has significantly reduced in size achieving partial response by RECIST 1.1. Reduction in T2 signal following treatment also implies response.
See this image and copyright information in PMC

References

    1. Fisher C, Thway K. Aggressive fibromatosis. Pathology 2014;46:135–140. - PubMed
    1. Demoid Tumor Working Group . The management of desmoid tumours: A joint global consensus‐based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96–107. - PubMed
    1. Gronchi A, Jones RL. Treatment of desmoid tumors in 2019. JAMA Oncol 2019;5:567–568. - PubMed
    1. Palassini E, Frezza AM, Mariani L et al. Long‐term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid‐type fibromatosis. Cancer J 2017;23:86–91. - PubMed
    1. Weiss AJ, Lackman RD. Low‐dose chemotherapy of desmoid tumors. Cancer 1989;64:1192–1194. - PubMed

Publication types

LinkOut - more resources